Skip to main content
CMMB
NASDAQ Life Sciences

Chemomab Sets Dec 4 Vote on Scipher Merger; Holders Get 32% of Combined Company

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.12
Mkt Cap
$7.898M
52W Low
$0.92
52W High
$3.227
52W Position info
22% above low
Off High info
65% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

CMMB sits 22% above its 52-week low of $0.92 on elevated volume (2.2× avg).

Summary

Chemomab filed the definitive proxy for a December 4, 2026 special meeting on its merger with Scipher, where holders would own about 32% of the combined company before a $30-50 million PIPE cuts that to roughly 26.7%.


Key Events · M&A and Partnerships · CMMB

  • Special Meeting Set for December 4

    Shareholders of record on October 29, 2026 will vote on six proposals; closing requires approval of Proposals 1 through 4 (merger, domestication, Nasdaq issuance, directors).

  • Chemomab Holders Keep 32% Pre-PIPE

    In a $150 million combined valuation, Chemomab is valued at $48 million and Scipher at $102 million; before the PIPE, Chemomab holders get 32% and Scipher noteholders 68%.

  • PIPE Cuts Chemomab to 26.7%

    A $30-50 million PIPE at a $150 million combined valuation with 100% warrant coverage at 50% of valuation leaves Chemomab holders at about 26.7%, Scipher noteholders at 56.7% and PIPE investors at 16.6%.

  • CVRs Pay Up to $50 Million

    Holders receive CVRs paying $40 million on a nebokitug PSC Phase 3 start or disposition and $10 million on FDA approval in any indication, within a seven-year term; the CVRs will not be listed or traded.


Analysis · CMMB · Life Sciences

The definitive proxy now puts the Scipher merger to a shareholder vote on December 4, 2026. Before a $30-50 million PIPE that cuts them to about 26.7%, Chemomab holders would keep roughly 32% of the combined company, with Scipher noteholders at 56.7% and PIPE investors at 16.6%. Effectively a referendum on the only funded path forward, the vote comes as Chemomab had about $6.7 million of cash at June 30, 2026 and has said substantial doubt exists about continuing as a going concern absent the merger or new financing. Holders also receive CVRs worth up to $40 million on a nebokitug PSC Phase 3 or disposition and $10 million on any FDA approval, but those are contractual, non-traded rights that may never pay. Approval of Proposals 1 through 4 is required; failure to close leaves Chemomab to raise money alone or consider liquidation.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CMMB was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $0.92 to $3.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CMMB - Latest Insights

CMMB
Nov 10, 2026, 5:30 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.53 info
Change: +$0.185 (+14%) info
Market Cap: $11.086M info
CMMB
Nov 10, 2026, 5:26 PM EST
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $1.53 info
Change: +$0.185 (+14%) info
Market Cap: $11.086M info
CMMB
Oct 19, 2026, 5:28 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.53 info
Change: +$0.340 (+29%) info
Market Cap: $11.086M info
CMMB
Sep 30, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.19
Real-time Price: $1.53 info
Change: +$0.340 (+29%) info
Market Cap: $11.086M info
CMMB
Sep 25, 2026, 5:28 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $1.53 info
Change: -$0.6398 (-29%) info
Market Cap: $11.086M info